CoChat

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

The DOI matches its Crossref record.

Abstract

Introduction: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by expression of B-cell maturation antigen (BCMA). Elranatamab (PF-06863135), a bispecific antibody that targets BCMA and CD3 on T-cells, activates and redirects the T-cell mediated immune response against MM. This clinical trial, MagnetisMM-1 (NCT03269136), is the ongoing Phase 1 first-in-human study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of elranatamab for patients (pts) with relapsed or refractory MM. Methods: Elranatamab was administered subcutaneously (SC) at doses from 80 to 1000µg/kg either weekly or every 2 weeks. Treatment-emergent adverse events (TEAEs) were graded by National Cancer Institute Common Terminology Criteria for Adverse Events (v4.03), whereas cytokine release syndrome (CRS) was assessed by criteria of the American Society for Transplantation and Cellular Therapy. PK, cytokines, lymphocyte subsets, and soluble BCMA were analyzed over time. Clinical response was assessed by criteria of the International Myeloma Working Group (IMWG). Minimal residual disease (MRD) was assessed by next generation sequencing at a sensitivity of 1×10-5 in accordance with IMWG criteria. Results: A total of 55 pts received single-agent elranatamab SC at a dose ≥215μg/kg as of 22-Jun-2022. Median age was 64 (range 42-80) years, and 27% of pts were Black/African American or Asian. Median number of prior regimens was 5 (range 2-14), 91% were triple-class refractory, 69% had prior stem cell transplantation, 29% had high cytogenetic risk, and 24% received prior BCMA-targeted therapy. The most common TEAEs regardless of causality included CRS, neutropenia, anemia, injection site reaction, and lymphopenia. With pre-medication and a single priming dose (600µg/kg or 44mg), the overall incidence of CRS at the recommended dose (1000µg/kg or 76mg) was 67% and limited to Grade 1 (33%) or Grade 2 (33%), with no events Grade 3 or higher. Elranatamab exposure was dose dependent. Cytokine increases occurred with the first dose and were reduced by pre-medication. Soluble BCMA decreased with disease response, elranatamab therapy was associated with increased peripheral T-cell proliferation, and median time to response was 36 days (range 7-262). With a median follow-up of 12.0 months (range 0.3-29.0) and including only IMWG confirmed responses, the objective response rate (ORR) was 64% (95% CI 50-75%) with 56% of pts (31/55) achieving very good partial response (VGPR) or better and 38% of pts (21/55) achieving complete response (CR) or better. Among 13 pts with prior BCMA-directed therapy (antibody drug conjugate, chimeric antigen receptor T-cell therapy, or both), 54% (7/13) achieved response including 46% (6/13) with VGPR or better. For responders (n=35), the probability of being event-free at 12 months was 59% (95% CI 39-74%) and the Kaplan-Meier estimate for median duration of response was 17.1 months (95% CI 10.6-NE). Single-agent elranatamab induced durable clinical and molecular responses, and 100% (12/12) of evaluable pts with confirmed CR or better achieved MRD negativity at a sensitivity of 1×10-5 including 2 pts with MRD negativity and ongoing stringent CR beyond 2 years. Conclusions: Elranatamab induced durable clinical and molecular responses for pts with relapsed or refractory MM. The ORR was 64% with more than half of these pts (38%) achieving CR or better, and 100% of evaluable pts achieved MRD negativity. Together with emerging data from pivotal studies MagnetisMM-3 (NCT0469359) and MagnetisMM-5 (NCT05020236), these results support further development of elranatamab for patients with MM.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2022-166494

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 46

Metadata

Authors
Raje, N., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., Skoura, A., Chan, E. M., Trudel, S., Jakubowiak, A., Chu, M. P., Gasparetto, C. J., Dalovisio, A. P., Sebag, M., & Lesokhin, A. M.
Affiliations
  • Harvard University (US)
  • University of Calgary (CA)
  • University of California San Diego (US)
  • Vanderbilt-Ingram Cancer Center (US)
  • Northside Hospital (US)
  • Baylor Scott & White Health (US)
  • University of Iowa (US)
  • Pfizer (United States) (US)
  • University Health Network (CA)
  • University of Chicago Medical Center (US)
  • Cross Cancer Institute (CA)
  • Duke Cancer Institute (US)
  • Ochsner Health System (US)
  • 18Cedars Cancer Center, McGill University Health Centre, Montreal, Canada
  • Memorial Sloan Kettering Cancer Center (US)
Venue
Blood
Published
2022-11-15
Volume
140
Issue
Supplement 1
Pages
388-390
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4310096227
Cited by
46
References
0
Citations by year
2026: 4 · 2025: 6 · 2024: 9 · 2023: 25
FWCI
7.27
Type
journal article
Language
en
Open access
closed
Locations
Blood (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
elranatamab, BCMA, multiple myeloma, relapsed/refractory multiple myeloma, CD3, cytokine release syndrome, minimal residual disease, durable response, pharmacokinetics, pharmacodynamics, immunotherapy, subcutaneous administration, soluble BCMA, lymphocyte subsets, treatment-emergent adverse events

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma. https://app.cochat.ai/papers/10.1182/blood-2022-166494
The paper
Raje, N., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., Skoura, A., Chan, E. M., Trudel, S., Jakubowiak, A., Chu, M. P., Gasparetto, C. J., Dalovisio, A. P., Sebag, M., & Lesokhin, A. M. (2022). Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma. Blood. https://doi.org/10.1182/blood-2022-166494

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.